DossierENTITY

Myqorzo

Coverage of Myqorzo in the Nexus archive.

Earliest in view: May 5 · 11:30 UTCMost recent: May 5 · 11:30 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHMay 5 · 11:30 UTCSTAT NEWS
STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
Cytokinetics' drug Myqorzo met efficacy goals in a Phase 3 clinical trial for non-obstructive hypertrophic cardiomyopathy, a genetic heart disease. The trial's success could expand treatment eligibility and boost peak sales to $5 billion annually. Myqorzo is already in commercial launch for a more severe form of the disease.